Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics

Dr. Reddy's Laboratories Ltd (RDY): $67.70

0.53 (-0.78%)

POWR Rating

Component Grades








RDY Price/Volume Stats

Current price $67.70 52-week high $73.17
Prev. close $68.23 52-week low $51.11
Day low $67.54 Volume 125,900
Day high $68.23 Avg. volume 240,358
50-day MA $66.33 Dividend yield 0.61%
200-day MA $62.18 Market Cap 11.30B

RDY Stock Price Chart Interactive Chart >


  • Stability is the dimension where RDY ranks best; there it ranks ahead of 92.56% of US stocks.
  • The strongest trend for RDY is in Quality, which has been heading down over the past 177 days.
  • RDY's current lowest rank is in the Momentum metric (where it is better than 6.74% of US stocks).

RDY Stock Summary

  • Price to trailing twelve month operating cash flow for RDY is currently 0.16, higher than just 1.08% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of -70.52%, DR REDDYS LABORATORIES LTD's debt growth rate surpasses only 2.87% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for RDY comes in at 44.24% -- higher than that of 95.46% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to DR REDDYS LABORATORIES LTD, a group of peers worth examining would be ITT, CMCM, NSSC, SRTS, and APDN.
  • RDY's SEC filings can be seen here. And to visit DR REDDYS LABORATORIES LTD's official web site, go to www.drreddys.com.

Dr. Reddy's Laboratories Ltd (RDY) Company Bio

Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.

RDY Latest News Stream

Event/Time News Detail
Loading, please wait...

RDY Latest Social Stream

Loading social stream, please wait...

View Full RDY Social Stream

Latest RDY News From Around the Web

Below are the latest news stories about DR REDDYS LABORATORIES LTD that investors may wish to consider to help them evaluate RDY as an investment opportunity.

Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Yahoo | November 2, 2023

Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates

Dr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.

Yahoo | October 30, 2023

Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q2 2024 Earnings Call Transcript

Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q2 2024 Earnings Call Transcript October 27, 2023 Dr. Reddy’s Laboratories Limited beats earnings expectations. Reported EPS is $1.07, expectations were $0.88. Operator: Ladies and gentlemen, good day, and welcome to the Dr. Reddy’s Q2 FY ’24 Earnings Conference Call. [Operator Instructions]. Please note that this conference is being recorded. […]

Yahoo | October 29, 2023

Dr. Reddy’s Q2 FY24 Financial Results

HYDERABAD, India, October 27, 2023--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter ended Sep 30, 2023.

Yahoo | October 27, 2023

All You Need to Know About Doctor Reddy's (RDY) Rating Upgrade to Strong Buy

Doctor Reddy's (RDY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Yahoo | October 26, 2023

Read More 'RDY' Stories Here

RDY Price Returns

1-mo 4.07%
3-mo -1.54%
6-mo 22.82%
1-year 25.66%
3-year 7.03%
5-year 84.96%
YTD 32.48%
2022 -19.92%
2021 -7.49%
2020 76.61%
2019 8.38%
2018 1.18%

RDY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RDY Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!